News
Lilly Pill Cuts Body Weight by 10.5% in Patients With Type 2 Diabetes
Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in patients without diabetes sent company shares tumbling.
Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.
Investor's Business Daily on MSN37m
Eli Lilly's 'Surprising Development' In Obesity Just Slammed Viking, Novo Stocks
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful Phase 3 study.
Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.
Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...
Around 14% of study participants given the high lepodisiran dose experienced “treatment-emergent” adverse events, but none were serious or led them to drop out of the trial, Lilly said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback